NasdaqGS:VTRSPharmaceuticals
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win
Viatris Inc. recently reported second quarter 2025 financial results exceeding analyst expectations and reaffirmed its outlook for the year, alongside securing FDA approval for its Iron Sucrose Injection, the first generic version of Venofer® Injection, for the treatment of iron deficiency anemia in chronic kidney disease patients.
An interesting aspect is the FDA’s competitive generic therapy designation for key strengths of Iron Sucrose Injection, granting Viatris 180 days of shared...